Nektar Therapeutics
NKTR
40.26
+0.35
+0.88%
Nektar Therapeutics
US · NKTR
#3017 by market cap
Listed 1970
40.26
+0.35
+0.88%
Live - 5344 symbols - heartbeat 126s ago
· 2026-10-08 07:38
Pre-market
39.20
-2.63%
After-hours
40.00
-0.65%
Overnight
40.20
-0.15%
- Market cap
- 1.37B
- P/E (TTM)i
- -6.58
- P/Bi
- 1.52
- EPSi
- -9.73
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on NKTR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -14.88, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -43.89% YoY
Margins
- Gross margin
- 100.00%
- Operating margin
- -236.77%
- Net margin
- -297.07%
Key ratios & quality
- Altman Z-Scorei
- -14.88
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.19B | 114.62M | 152.92M | 101.91M | 92.06M | 90.12M | 98.43M | 55.23M |
| Gross profit | 1.17B | 93.24M | 133.44M | 77.01M | 70.42M | 56.35M | 67.74M | 55.23M |
| Selling & admin expenses | 81.44M | 98.71M | 104.68M | 122.84M | 92.33M | 77.42M | 76.75M | 68.67M |
| Research & development | 399.54M | 434.57M | 408.68M | 400.27M | 218.32M | 114.16M | 120.91M | 117.33M |
| Operating profit | 687.93M | -440.04M | -379.92M | -446.10M | -240.24M | -135.23M | -129.92M | -130.77M |
| Pretax profit | 682.73M | -440.05M | -443.95M | -523.28M | -364.98M | -276.26M | -119.20M | -155.49M |
| Tax | 1.41M | 613.00K | 493.00K | 557.00K | 3.22M | -200.00K | -239.00K | -138.00K |
| Net profit | 681.31M | -440.67M | -444.44M | -523.84M | -368.20M | -276.06M | -118.96M | -164.08M |
| Basic EPS | 60 | -38 | -37 | -43 | -30 | -22 | -9 | -10 |
| Diluted EPS | 56.70 | -37.80 | -37.35 | -42.90 | -29.55 | -21.75 | -8.68 | -9.73 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 10.46M | 11.18M | 11.79M | 21.81M | 10.86M | 10.13M |
| Gross profit | -- | -- | 11.79M | 21.81M | -- | -- |
| Selling & admin expenses | 24.35M | 17.07M | 16.07M | 11.19M | 13.44M | 12.77M |
| Research & development | 30.48M | 29.89M | 27.25M | 29.71M | 35.68M | 39.13M |
| Operating profit | -44.37M | -35.78M | -31.53M | -19.09M | -38.26M | -41.76M |
| Pretax profit | -46.37M | -39.40M | -35.02M | -34.70M | -43.09M | -40.30M |
| Tax | 52.00K | -188.00K | -33.00K | 31.00K | 64.00K | 2.00K |
| Net profit | -50.88M | -41.59M | -35.52M | -36.08M | -44.90M | -40.62M |
| Basic EPS | -4 | -3 | 2 | -2 | -2 | -1 |
| Diluted EPS | -3.62 | -2.95 | 1.87 | -1.78 | -1.82 | -1.23 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.44B | 1.42B | 1.14B | 795.58M | 545.97M | 330.70M | 261.29M | 266.27M |
| Cash & ST investments | 1.34B | 1.32B | 1.06B | 733.96M | 504.98M | 303.62M | 255.23M | 245.75M |
| Inventory | 11.38M | 12.67M | 15.29M | 15.80M | 19.20M | 16.10M | -- | -- |
| Total assets | 2.15B | 1.98B | 1.54B | 1.12B | 710.60M | 398.03M | 303.85M | 280.41M |
| Total current liabilities | 82.00M | 353.89M | 115.78M | 85.20M | 68.20M | 51.27M | 61.40M | 53.54M |
| Short-term debt | -- | 265.41M | 13.92M | 17.44M | 18.67M | 19.26M | 19.87M | 20.50M |
| Long-term debt | 246.95M | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 432,597,000.00 | 571,965,000.00 | 461,472,000.00 | 437,681,000.00 | 343,962,000.00 | 267,046,000.00 | 243,113,000.00 | 190,574,000.00 |
| Total equity | 1.72B | 1.41B | 1.08B | 679.51M | 366.64M | 130.99M | 60.74M | 89.83M |
| Retained earnings | -1.42B | -1.86B | -2.31B | -2.83B | -3.20B | -3.48B | -3.60B | -3.76B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 229.91M | 186.57M | 281.36M | 266.27M | 589.04M | 739.40M |
| Cash & ST investments | 218.63M | 175.90M | 270.21M | 245.75M | 568.60M | 684.34M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 256.24M | 207.53M | 301.35M | 280.41M | 763.27M | 1.10B |
| Total current liabilities | 70.93M | 71.39M | 66.34M | 53.54M | 57.71M | 70.99M |
| Short-term debt | 21.84M | 22.01M | 22.18M | 20.50M | 22.53M | 22.71M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 242,503,000.00 | 231,745,000.00 | 216,261,000.00 | 190,574,000.00 | 187,055,000.00 | 192,008,000.00 |
| Total equity | 13.74M | -24.21M | 85.09M | 89.83M | 576.22M | 903.12M |
| Retained earnings | -3.65B | -3.69B | -3.72B | -3.76B | -3.81B | -3.85B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 718.21M | -328.68M | -313.29M | -412.66M | -304.01M | -192.61M | -175.71M | -208.51M |
| Depreciation & amortization | 10.87M | 13.16M | 14.18M | 14.15M | 13.03M | 7.82M | 4.39M | 1.03M |
| Free cash flow | 703.98M | -354.97M | -320.55M | -427.65M | -309.68M | -193.47M | -177.18M | -208.68M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 790.23M | -- | -- | -- | -- | 0 | -3.00M | 180.85M |
| Ending cash balance | 194.91M | 96.36M | 198.96M | 25.22M | 88.23M | 35.28M | 44.25M | 15.12M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -49.05M | -45.74M | -48.76M | -64.96M | -44.30M | -75.77M |
| Depreciation & amortization | 426.00K | 214.00K | 196.00K | 190.00K | 151.00K | 156.00K |
| Free cash flow | -49.06M | -45.78M | -48.88M | -64.98M | -44.32M | -75.86M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 142.59M | 38.26M | 525.52M | 364.91M |
| Ending cash balance | 38.89M | 42.99M | 41.03M | 15.12M | 149.58M | 39.27M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 75.47 | -28.22 | -35.80 | -59.64 | -70.39 | -110.95 | -124.10 | -217.94 |
| ROA %i | 51.25 | -21.35 | -25.28 | -39.45 | -40.29 | -49.80 | -33.90 | -56.17 |
| ROIC %i | 59.76 | -21.84 | -28.36 | -47.91 | -53.09 | -72.23 | -51.15 | -87.55 |
| 5-year avg ROE %i | -- | -153.41 | -84.64 | -31.62 | -23.72 | -61.00 | -80.18 | -116.60 |
| EBIT margin %i | 60.80 | -343.49 | -266.05 | -467.06 | -365.08 | -278.42 | -92.54 | -234.11 |
| FCF / sales %i | 58.99 | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 17.53 | 4.02 | 9.83 | 9.34 | 8.00 | 6.45 | 4.26 | 4.97 |
| Quick ratioi | 16.81 | 3.85 | 9.51 | 8.88 | 7.53 | 5.97 | 4.18 | 4.62 |
| Debt / assetsi | 11.49 | 20.64 | 9.77 | 12.82 | 18.50 | 29.59 | 33.75 | 30.58 |
| LT debt / equityi | 14.38 | 10.16 | 12.66 | 18.50 | 30.77 | 75.21 | 136.15 | 72.64 |
| Interest coveragei | 16.96 | -8.49 | -10.96 | -10.06 | -11.62 | -9.90 | -3.24 | -4.94 |
| Revenue CAGR (3Y) %i | 72.92 | -11.51 | -20.79 | -55.96 | -7.05 | -16.16 | -1.15 | -15.66 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -189.46 | -440.80 | -180.24 | -217.94 | -53.60 | -35.76 |
| ROA %i | -40.79 | -44.39 | -39.63 | -56.17 | -31.01 | -24.12 |
| ROIC %i | -66.88 | -81.15 | -62.75 | -87.55 | -36.40 | -28.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -115.96 | -119.13 | -139.32 | -234.11 | -221.19 | -223.76 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.24 | 2.61 | 4.24 | 4.97 | 10.21 | 10.42 |
| Quick ratioi | 3.11 | 2.48 | 4.09 | 4.62 | 9.92 | 9.71 |
| Debt / assetsi | 39.16 | 46.33 | 30.50 | 30.58 | 10.90 | 7.17 |
| LT debt / equityi | 571.37 | -- | 81.95 | 72.64 | 10.52 | 6.18 |
| Interest coveragei | -3.67 | -3.36 | -3.28 | -4.94 | -4.22 | -3.94 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Develop novel drug candidates100.00%
Quote time 2026-10-08 07:38:31 · For reference only, not investment advice and not tailored to your situation.